BPC-157 and TB-500: Identity and Evidence Boundaries

Scope of this reference

This page concerns the catalogue identity of two separately listed laboratory materials, BPC-157 and TB-500, and the boundaries of what published literature and batch analysis establish about them. It is not a treatment guide, a recommendation, a human-use protocol or evidence that either material is safe or effective in people or animals.

Two distinct materials, not two names for one thing

BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids. Its sequence corresponds to a partial sequence described in the literature on a protein isolated from gastric juice, which is the origin of the "body protection compound" naming. The material supplied is manufactured synthetically and is not extracted from a biological source. It is listed as BPC-157.

TB-500 is a synthetic peptide corresponding to a short region of thymosin beta-4, a 43-residue protein. TB-500 is a *fragment*, not the full-length protein, and the two are not interchangeable in either nomenclature or evidence. It is listed as TB-500.

The two therefore differ in length, sequence origin and parent molecule. Materials listed under both names appear in the tissue signalling collection.

Why the fragment distinction matters when reading studies

A large part of the published literature indexed under "thymosin beta-4" concerns the full-length protein, not the fragment supplied as TB-500. Findings reported for a full-length protein cannot be transferred to a shorter synthetic fragment without evidence specific to that fragment. The same caution applies in reverse.

This is the single most common error in material descriptions for these two compounds, and it is a question of identity rather than interpretation.

The blend presentation

A combined presentation supplying both materials in one vial is listed as BPC-157 + TB-500, alongside other research blends. Two points follow from the catalogue facts alone:

• •A blend is a supply format. Combining two materials in one vial does not generate evidence about the combination.
• •There is no published literature on this pairing *as a pairing*. The available literature concerns the individual materials, studied separately, overwhelmingly in non-human models.

Statements that attribute properties to the combination are therefore not supported by the evidence base for the components, and we do not make them.

Reading the evidence by tier

Published findings for both materials must be read according to the model that produced them:

• •In-vitro — assays, cell lines and isolated tissue. Establishes behaviour in that system only.
• •Animal models — predominantly rodent. Establishes findings in that species under those conditions.
• •Human data — the tier where claims about people could be grounded, and the tier where the literature on both of these materials is thin to absent.

Most of what is published about BPC-157 and TB-500 sits in the first two tiers. Describing a preclinical finding in language that implies a demonstrated human outcome misrepresents the source, regardless of how many sources are cited.

What analytical documentation establishes

A certificate of analysis provides evidence about the particular batch tested: its identity, measured composition and purity by the stated method. It does not establish a biological, therapeutic or physiological outcome, and it does not extend to other batches.

For either material, check the full name and SKU, the supplied quantity and physical form, the batch number, whether a report exists for that same batch, and the method, laboratory, date and stated limitations of that report. Available reports are published in our COA library; the guides to reading a peptide COA and understanding HPLC purity explain what those documents can and cannot show.

Laboratory-use boundary

Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.

We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.